Purdue Continued Pitching OxyContin Despite Concerns Raised By Sales Reps, New Suit From Pennsylvania Alleges

This post was originally published on this site

The suit says Purdue drug representatives have made 531,000 detailing calls on doctors in the state since 2007, when the company settled with Pennsylvania and 25 other states agreeing to stop identifying illegal diversion of its OxyContin and to promote it only for federally approved uses. The company is facing a barrage of legal challenges from local counties, states and other parties eager to hold it accountable for the role it played in the opioid epidemic.